文献速递心律失常

不对称与对称二甲基精氨酸预测房颤患者结局:ARISTOTLE 子研究

Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy.
PubMed 文献 · J Am Coll Cardiol · 2018-01-01

该研究基于 ARISTOTLE 试验中 5,004 例房颤患者的血浆样本,检测 ADMA 与 SDMA 浓度并随访中位 1.9 年。调整既定危险因素和治疗后,ADMA 三分位组与卒中/系统性栓塞(p=0.034)及死亡(p<0.0001)相关,SDMA 三分位组与大出血和死亡相关(均 p<0.001)。将二者纳入 CHA2DS2-VASc 或 HAS-BLED 模型可改善相应结局的 C 指数。

要点

  • ADMA 升高与房颤患者卒中/系统性栓塞及死亡相关。
  • SDMA 升高与房颤患者大出血及死亡相关。
  • ADMA/SDMA 加入 CHA2DS2-VASc 或 HAS-BLED 可改善预测 C 指数。

核心结论

  • 在抗凝房颤患者中,ADMA 升高与血栓栓塞事件呈弱关联,SDMA 升高与出血事件相关,两者均与死亡率升高强相关。
  • 结果提示一氧化氮功能紊乱可能同时调节抗凝房颤患者的血栓与出血风险。

研究设计与样本

  • 研究为 ARISTOTLE 试验子研究,纳入随机分配至华法林或阿哌沙班的 5,004 例房颤患者。
  • 采用高效液相色谱法测定血浆 ADMA 与 SDMA 浓度,随访中位 1.9 年。
  • 采用多变量分析评估与临床特征的关系,并用校正 Cox 比例风险模型评估与主要结局的关联。

主要发现

  • ADMA 与 SDMA 血浆浓度均随年龄、女性、肾功能损害、永久性房颤或充血性心力衰竭显著升高。
  • ADMA 与 SDMA 均随 CHA2DS2-VASc 和 HAS-BLED 评分升高而升高(p<0.001),但在糖尿病患者中降低。
  • 校正既定危险因素和治疗后,ADMA 三分位组与卒中/系统性栓塞(p=0.034)及死亡(p<0.0001)显著相关。
  • SDMA 三分位组与大出血和死亡相关(均 p<0.001)。
  • 将 ADMA 和 SDMA 纳入 CHA2DS2-VASc 或 HAS-BLED 预测模型可改善相应结局的 C 指数。

临床怎么用

  • 在抗凝房颤患者中,ADMA 与 SDMA 可作为血栓栓塞、出血及死亡风险的潜在生物标志物。
  • 将 ADMA 和 SDMA 纳入 CHA2DS2-VASc 或 HAS-BLED 模型可能改善风险预测,但尚需外部验证。
  • ADMA 与 SDMA 不用于指导华法林或阿哌沙班的选择。

局限性

  • 原文摘要未报告研究局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is little mechanistic information on factors predisposing atrial fibrillation (AF) patients to thromboembolism or bleeding, but generation of nitric oxide (NO) might theoretically contribute to both. OBJECTIVES: The authors tested the hypothesis that plasma levels of the methylated arginine derivatives asymmetric and symmetric dimethylarginine (ADMA/SDMA), which inhibit NO generation, might be associated with outcomes in AF. METHODS: Plasma samples were obtained from 5,004 patients with AF at randomization to warfarin or apixaban in the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) trial. ADMA and SDMA concentrations were measured by high-performance liquid chromatography. Relationships to clinical characteristics were evaluated by multivariable analyses. Associations with major outcomes, during a median of 1.9 years follow-up, were evaluated by adjusted Cox proportional hazards models. RESULTS: Both ADMA and SDMA plasma concentrations at study entry increased significantly with patients' age, female sex, renal impairment, permanent AF, or congestive heart failure. ADMA and SDMA increased (p < 0.001) with both increased CHA2DS2-VASc and HAS-BLED scores, but decreased in the presence of diabetes. On multivariable analysis adjusting for established risk factors and treatment, tertile groups of ADMA concentrations were significantly associated with stroke/systemic embolism (p = 0.034), and death (p < 0.0001), whereas tertile groups of SDMA were associated with major bleeding and death (p < 0.001 for both). Incorporating ADMA and SDMA into CHA2DS2-VASc or HAS-BLED predictive models improved C-indices for those outcomes. Neither ADMA nor SDMA predicted differential responses to warfarin or apixaban. CONCLUSIONS: In anticoagulated patients with AF, elevated ADMA levels are weakly associated with thromboembolic events, elevated SDMA levels with bleeding events and both are strongly associated with increased mortality. These findings suggest that disturbances of NO function modulate both thrombotic and hemorrhagic risk in anticoagulated patients with AF. (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation [ARISTOTLE]; NCT00412984).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Horowitz JD, De Caterina R, Heresztyn T, et al. Asymmetric and Symmetric Dimethylarginine Predict Outcomes in Patients With Atrial Fibrillation: An ARISTOTLE Substudy. J Am Coll Cardiol. 2018. PMID: 30092948. doi:10.1016/j.jacc.2018.05.058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。